Speaker Profile
Ph.D., Chief Scientific Officer, Precede Biosciences
Biography
Carl is a renowned professional in the field of translational medicine and diagnostics with over 17 years of experience in drug development and technology advancement. In his previous role as the Vice President and Head of Oncology Translational Medicine at AstraZeneca Pharmaceuticals, he led a global team, spearheading biomarker strategy and translational sciences to support oncology drug development. Carls career also includes leadership positions at Novartis Institutes for BioMedical Research and the National Cancer Institute. He has made significant contributions to the field, with over 600 publications to his name and a reputation for mentoring future leaders in the pharmaceutical and biomedical sectors. Driven by a passion for lifelong learning and effective communication, he continues to shape the landscape of healthcare innovation.
Talk
Comprehensive Epigenomic Profiling from Plasma to Inform Therapy Selection
Precede Bio's novel liquid biopsy platform interrogates genome-wide transcriptional biology from 1 mL of plasma through analysis of DNA associated with histone marks of active transcription. This comprehensive multi-analyte epigenomic profiling approach has the potential to investigate the transcriptional status of individual genes and genome-wide biology that is correlated or anti-correlated with targets of interest.
Genomic Profiling Showcase:
Precede Biosciences
Precede Bio is impacting the development and use of precision medicines with a first-in-class
comprehensive epigenomic liquid biopsy platform
designed to reveal the fundamental biology behind disease at any given moment so that researchers and clinicians can better target medicines to the right patients.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2024 Genomic Profiling Showcase will provide a 15 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.
